COMMUNIQUÉS West-GlobeNewswire

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16/07/2026
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
16/07/2026
Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas LAS VEGAS, July 16, 2026 [...]
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET [...]
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
16/07/2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, [...]
Marius Pharmaceuticals Welcomes Department of Defense's New Testosterone Screening Initiative for U.S. Service Members
16/07/2026
RALEIGH, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. , a specialty pharmaceutical company advancing the science of testosterone therapy and hormone health, today welcomed Defense Secretary Pete [...]
CDT Equity Inc. Announces Reverse Stock Split
16/07/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of [...]
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
16/07/2026
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
16/07/2026
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX ® -C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary [...]
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
16/07/2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE [...]
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
16/07/2026
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats TORONTO, July 16, 2026 (GLOBE [...]
4TEEN4 Receives U.S. FDA Fast Track Designation for Invobenitug in Cardiogenic Shock
16/07/2026
Hennigsdorf/Berlin, July 16, 2026 – 4TEEN4 Pharmaceuticals GmbH today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (formerly known as procizumab), for the [...]
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026
First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malformations (AVMs) in [...]
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- BienRaíz today announced the launch of BienRaíz Magnesium Glycinate Supplement, a daily magnesium glycinate supplement formulated with 240 mg elemental magnesium per serving. [...]
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026
Sales Highlights (unaudited): Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp) 2H FY26 sales AUD$3.5 million up 7% on pcp 4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 [...]
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026
www.arlettapharmasolutions.com FDA endorses key elements of the proposed Phase 2 dose-ranging study and openness to a single pivotal Phase 3 study to support a future NDA Amsterdam, the Netherlands, 16 July 2026 — [...]
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
16/07/2026
July 16, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
16/07/2026
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst’s [...]
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
16/07/2026
Boehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people living with obesity and overweight. 1 BI 3034701 is a [...]

Pages